Fuse Medical, Inc. is a distributor of medical devices. It provides a broad portfolio of orthopedic implants, including internal and external fixation products; upper and lower extremity plating; total joint reconstruction; soft tissue fixation and augmentation for sports medicine procedures; full spinal implants for trauma, degenerative disc disease, and deformity indications; human allografts, substitute bone materials, and tendons; and regenerative tissues and fluids to augment orthopedic surgeries and wound care. The company was founded in 1968 and is headquartered in Richardson, TX.

Company profile
Ticker
FZMD
Exchange
Website
CEO
Christopher C. Reeg
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
AMERICAN METALS SERVICE INC, GOLF ROUNDS COM INC
SEC CIK
Corporate docs
Subsidiaries
CPM Medical Consultants, LLC ...
IRS number
591224913
FZMD stock data
Investment data
Securities sold
Number of investors
Calendar
12 May 22
26 Jun 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 522.49K | 522.49K | 522.49K | 522.49K | 522.49K | 522.49K |
Cash burn (monthly) | 10.23K | 2.56K | 117.81K | 176.58K | (no burn) | 100.06K |
Cash used (since last report) | 29.37K | 7.34K | 338.13K | 506.81K | n/a | 287.18K |
Cash remaining | 493.11K | 515.14K | 184.36K | 15.67K | n/a | 235.31K |
Runway (months of cash) | 48.2 | 201.3 | 1.6 | 0.1 | n/a | 2.4 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Dec 21 | Brooks Mark W | Common Stock | Gift | Dispose G | Yes | No | 0 | 107,143 | 0 | 54,620,130 |
4 Nov 21 | Brooks Mark W | Grant | Acquire A | No | No | 0.68 | 73,530 | 50K | 549,253 | |
4 Nov 21 | Reeg Christopher C | Grant | Acquire A | No | No | 0.68 | 73,530 | 50K | 549,253 |
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Financial report summary
?Risks
- We may not be able to refinance, extend or repay our indebtedness owed to our secured lender, which would have a material adverse effect on our business, future operating results, and financial condition.
- The COVID-19 outbreak may decrease demand for our products and disrupt our supply chain, and any decrease in demand or supply chain disruption resulting from COVID-19 would adversely affect our revenues and results of operations.
- We have significant concentration in and dependence on a small number of customers.
- We are exposed to risks of obsolete and slow-moving inventory which may adversely impact our cash flow and liquidity.
- To grow revenues and profitability from certain products, we must expand our relationships with hospital systems, third-party distributors and independent sales representatives, whom we do not control.
- Our revenue growth and profitability will depend in large part upon the effectiveness of our marketing strategies and investments.
- Our revenues will depend on our customers’ continued receipt of adequate reimbursement from private insurers and government sponsored healthcare programs.
- Consolidation in the healthcare industry could lead to demands for price concessions or to the exclusion of some suppliers from certain of our markets, which could have an adverse effect on our business, financial condition or results of operations.
- Our operating earnings are dependent on certain significant suppliers.
- Interruption of manufacturing operations could adversely affect our business.
- Future business combinations or acquisitions may be difficult to integrate, which could cause us to shift our attention away from our primary business and its operations.
- If the statutes and regulations in our industry change, our business could be adversely affected.
- U.S. federal and state governmental regulation could restrict our ability to sell the products.
- The FDA regulates the manufacturers and suppliers of the products that we sell, market, manufacture, and distribute, and regulatory compliance is costly and could contribute to delays in the availability of our products.
- Future regulatory action remains uncertain.
- If we fail to obtain, or experience significant delays in obtaining, FDA clearances or approvals for our future products or modifications to our products, our ability to commercially distribute and market our products could suffer.
- Intellectual property litigation and infringement claims could cause us to incur significant expenses or prevent us from selling certain of our products.
- We operate our business in regions subject to natural disasters and other catastrophic events, and any disruption to our business resulting from natural disasters would adversely affect our revenue and results of operations.
- We cannot be certain that our internal controls over financial reporting and procedures will be sufficient in the future. This uncertainty could have a material adverse effect on our investors’ confidence in our reported financial information. There is no guarantee that our internal controls over financial reporting and procedures will not fail in the future.
- We depend on the knowledge and skills of our executives and other key employees, and if we are unable to retain and motivate them or recruit additional qualified personnel, our business may suffer.
- We may be adversely affected by product liability claims, unfavorable court decisions or legal settlements.
- We do business with companies that are owned or controlled by our Chief Executive Officer and Chairman of the Board and President, which could create actual or potential conflicts of interest.
- Some members of our executive team may dedicate inadequate time and attention to our Company.
- General economic conditions may adversely affect demand for our products and services.
- Because the market for our Common Stock is limited, persons who purchase our Common Stock may not be able to resell their shares at or above the purchase price they paid.
- Our current executive team can exert significant influence over our Company and make decisions that are not in the best interests of all stockholders.
- Under our charter documents and Delaware law, we could issue “blank check” preferred stock without stockholder approval, which would dilute our then current stockholders’ interests and impair such stockholders’ voting rights, discouraging a takeover that our stockholders may consider favorable.
- If our Common Stock becomes subject to a “chill” or a “freeze” imposed by the Depository Trust Company (“DTC”) our stockholders’ ability to sell shares may be limited.
Management Discussion
- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
- As used in this report on Form 10-Q, “we”, “us”, “our”, and the “Company” refer to Fuse Medical, Inc, a Delaware corporation.
- This discussion and analysis should be read in conjunction with the interim unaudited condensed consolidated financial statements of our Company and the related notes included in this report for the periods presented (our “Financial Statements”), the audited consolidated financial statements of our Company and the related notes thereto and the Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (our “2021 Annual Report”), filed with the Securities and Exchange Commission (the “SEC”) pursuant to Section 13 or 15(d) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on March 31, 2022.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
advantage, Advisory, affirmative, alternate, cease, cellular, CNH, commercialization, commercialize, competitive, comply, constitute, deposit, description, disruption, dissolution, dissolved, entirety, Exhibit, fact, floating, foregoing, harsh, innovative, launch, lead, lender, maximum, mitigate, mitigated, multiple, negative, newly, Omicron, optimize, osseointegration, osteo, pledge, Prime, raw, regionally, repay, SAB, Scientific, skin, source, surged, synthetic, text, turnover, World
Removed:
Carlo, certainty, contract, dependent, eligible, LOP, Monte, necessitated, order, Paycheck, reclassification, settlement, simulation, trailing, underlying
Financial reports
Current reports
8-K
Departure of Directors or Certain Officers
8 Apr 22
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
20 Dec 21
8-K
Departure of Directors or Certain Officers
3 Dec 21
8-K
Entry into a Material Definitive Agreement
11 Nov 21
8-K
Submission of Matters to a Vote of Security Holders
10 Jun 21
8-K
Fuse Medical, Inc. Announces Exclusive Agreement with Orthovestments, LLC for Manufacturing & Commercialization of the Orbitum ™ Staple System
1 Feb 21
8-K
Other Events
20 Jan 21
8-K
FUSE MEDICAL, INC. ANNOUNCES LAUNCH OF FuseChoiceTM BIOLOGICS PORTFOLIO
22 Dec 20
8-K
Fuse Medical, Inc. Files Quarterly Results on Form 10-Q and Provides Business Update In Response of COVID-19
14 Aug 20
8-K
Fuse Medical, Inc. Announces Engagement of Armanino LLP
19 Jun 20
Registration and prospectus
S-8
Registration of securities for employees
8 Jan 19
D
$3.28M in equity, sold $3.28M, 2 investors
20 Aug 18
D
$1.81M in equity, sold $1.81M, 5 investors
24 Oct 17
S-8
Registration of securities for employees
10 Oct 17
D
$720K in equity, sold $720K, 2 investors
3 Jan 17
D
Indefinite amount in equity, 49 investors
3 Jun 14
Proxies
DEFA14A
Additional proxy soliciting materials
10 May 22
DEFA14A
Additional proxy soliciting materials
27 Apr 21
DEFA14A
Additional proxy soliciting materials
27 Apr 20
DEFA14A
Additional proxy soliciting materials
5 Jun 19
DEFA14A
Additional proxy soliciting materials
13 May 19
DEF 14A
Definitive proxy
13 May 19
PRE 14A
Preliminary proxy
2 May 19
Other
UPLOAD
Letter from SEC
30 Sep 18
CT ORDER
Confidential treatment order
23 Aug 15
UPLOAD
Letter from SEC
29 Oct 14
CT ORDER
Confidential treatment order
20 Oct 14
CT ORDER
Confidential treatment order
20 Oct 14
CORRESP
Correspondence with SEC
21 Sep 14
UPLOAD
Letter from SEC
10 Sep 14
UPLOAD
Letter from SEC
17 Aug 14
CORRESP
Correspondence with SEC
4 Aug 14
CORRESP
Correspondence with SEC
30 Jul 14
Ownership
3
Fuse Medical / Lawrence Scott Yellin ownership change
26 May 22
5
Fuse Medical / Christopher C Reeg ownership change
23 Feb 22
5
Fuse Medical / Mark W Brooks ownership change
23 Feb 22
4
Fuse Medical / Renato V. Jr. Bosita ownership change
21 Dec 18
4
Fuse Medical / Ricky Raj S. Kalra ownership change
14 Dec 18
4
Fuse Medical / Mark W Brooks ownership change
14 Dec 18
4
Fuse Medical / Christopher C Reeg ownership change
14 Dec 18
4
Fuse Medical / William E McLaughlin III ownership change
14 Dec 18
4/A
Change in insider ownership (amended)
27 Nov 18
4/A
Fuse Medical / Christopher C Reeg ownership change
27 Nov 18